<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567253</url>
  </required_header>
  <id_info>
    <org_study_id>AGO/2015/002</org_study_id>
    <nct_id>NCT02567253</nct_id>
  </id_info>
  <brief_title>Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer</brief_title>
  <acronym>OvIP1</acronym>
  <official_title>Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OvIP1 study is designed to examine how drug dose and perfusion temperature affect the
      pharmacokinetics and pharmacodynamics of cisplatin used as (hyperthermic) intraperitoneal
      chemoperfusion, as an adjunct to surgery, in women with stage III epithelial ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage III ovarian cancer (OC) remains an important cause of cancer related mortality in
      women. After successful initial treatment, most patients eventually develop recurrent
      peritoneal disease which can only arise from peritoneal minimal residual disease (pMRD) left
      after primary cytoreductive surgery (CRS). Intensification of locoregional therapy through
      intraoperative intraperitoneal chemoperfusion (IPEC) immediately following CRS may prevent or
      delay peritoneal recurrence. Although IPEC, usually under hyperthermic conditions, is
      increasingly used in OC, its efficacy and the potential benefit of hyperthermia are at
      present unknown.The primary aim of this study is to assess the pharmacokinetic and
      pharmacodynamic properties of IP cisplatin administered under normothermic or hyperthermic
      conditions, and at different dosing schedules. Additional endpoints include surgery related
      morbidity and mortality, quality of life, overall survival, disease free survival, peritoneal
      recurrence free survival, peritoneal cytology, and exploration of potential biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue penetration distance of cisplatin in peritoneal tumor tissue nodules using laser-ablation inductively couples plasma mass spectrometry</measure>
    <time_frame>1 tumor nodule will be immediately fixed in liquid nitrogen after cytoreductive surgery and chemoperfusion. Frozen sections will be ablated through study completion</time_frame>
    <description>This will be analyzed via laser ablation-inductively coupled plasma- mass spectrometry (LA-ICP-MS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity and mortality will be measured using Dindo-Clavien classification</measure>
    <time_frame>Within 30 days after surgery and intraoperative intraperitoneal chemoperfusion</time_frame>
    <description>This will be estimated with the Dindo-Clavien classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific Quality of Life-C30</measure>
    <time_frame>3 weeks before operation, 6 weeks after and 3, 6, 12, 18 and 24 months after surgery and chemoperfusion</time_frame>
    <description>This will be investigated using the cancer-specific (C30) European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific Quality of Life-OV28</measure>
    <time_frame>3 weeks before operation, 6 weeks after and 3, 6, 12, 18 and 24 months after surgery and chemoperfusion</time_frame>
    <description>This will be investigated using the disease-specific (OV28) European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum perfusate concentration (Cmax) of cisplatin</measure>
    <time_frame>T=0min (before chemoperfusion), T=15min, T=30min, T=90min (during chemoperfusion); T=2h, T=3h, T=7.5h, T=24h (after start chemoperfusion)</time_frame>
    <description>Cisplatin (free + bounded) will be measured in perfusate, using high performance liquid chromatography coupled to an inductively coupled plasma- mass spectrometry (HPLC-ICP-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) and Area Under The Curve (AUC) of cisplatin</measure>
    <time_frame>T=0min (before chemoperfusion); T=15min, T=30min, T=90min (during chemoperfusion); T=2h, T=3h, T=7.5h, T=24h (after start chemoperfusion)</time_frame>
    <description>Cisplatin (free + bounded) will be measured in plasma, using high performance liquid chromatography coupled to an inductively coupled plasma- mass spectrometry (HPLC-ICP-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of cisplatin will be analyzed by visualizing the amount of DNA double-strand breaks (dsb) via the specific DNA-adduct immunohistochemical Liedert staining</measure>
    <time_frame>1 tumor nodule will be immediately fixed in 4% paraformaldehyde and immunohistochemical stainings will be done through study completion</time_frame>
    <description>PD of cisplatin will be studied via Pt-DNA adduct formation, using the Liedert staining which is specific for Pt-[Guanine, Guanine] adducts (Pt-[GG]) using Mab R-C18. The amount of double-strand breaks (dsb) will be analyzed then via fluorescence microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>Calculated from date of surgery until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>Time interval between date of surgery and disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal recurrence free survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>Time interval between date of surgery and peritoneal recurrence or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expression analysis of selected biomarkers = Excision repair cross-complementation group 1 (ERCC1), Methylguanine methyltransferase enzyme (MGMT), Breast cancer gene 1 (BRCA1), Copper transporter 1 (CTR1) using quantitative PCR</measure>
    <time_frame>1 tumor nodule will be immediately fixed in liquid nitrogen. Histological coupes will be made through study completion</time_frame>
    <description>Gene expression of potential predictive biomarkers using qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stromal composition and density of tumor tissues via analyzing collagen density, fibroblast Proliferation and DNA-intrastrand adduct formation of Pt-[GG]</measure>
    <time_frame>1 tumor nodule will be immediately fixed in 4% paraformaldehyde. Histological coupes will be made through study completion</time_frame>
    <description>Analyzing collagen density using the sirius red staining, analyzing fibroblast proliferation using alfa smooth-muscle action (α-SMA) stainings and DNA intrastrand adduct formation of Pt-[GG] with the Liedert staining using Mab R-C18</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>low dose, normothermic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose, normothermic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose, hyperthermic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose, hyperthermic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive surgery</intervention_name>
    <description>Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer</description>
    <arm_group_label>low dose, normothermic</arm_group_label>
    <arm_group_label>high dose, normothermic</arm_group_label>
    <arm_group_label>low dose, hyperthermic</arm_group_label>
    <arm_group_label>high dose, hyperthermic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPEC with Cisplatin (75mg/m²)</intervention_name>
    <description>Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min</description>
    <arm_group_label>low dose, normothermic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPEC with Cisplatin (100mg/m²)</intervention_name>
    <description>Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min</description>
    <arm_group_label>high dose, normothermic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)</intervention_name>
    <description>Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min</description>
    <arm_group_label>low dose, hyperthermic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIPEC with Cisplatin (100mg/m²)</intervention_name>
    <description>Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min</description>
    <arm_group_label>high dose, hyperthermic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Tumor type:

             * Biopsy proven serous epithelial ovarian carcinoma or peritoneal carcinoma

          -  Primary or recurrent disease

          -  Extent of disease:

               -  Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the
                  pelvis (FIGO stage III, Appendix (47))

               -  Stage IV with unilateral pleural fluid allowed

               -  Complete or nearly complete macroscopic cytoreduction at the time of surgery
                  (CC-0 or CC-1) deemed possible based on imaging, laparoscopy, or both

          -  Second-line patients; platinum sensitive

          -  Age over 18 years

          -  No major cardiac or respiratory disease

          -  Adequate performance status (Karnofsky index &gt; 70%)

          -  Adequate mental faculty, allowing to understand the proposed treatment protocol and
             provide informed consent

          -  Expected life expectancy more than 6 months

          -  Laboratory data:

               -  Serum creatinine ≤ 1.5 mg/dl or a calculated Glomerular Filtration Rate (GFR)
                  (CKD-EPI) ≥ 60 mL/min/1.73 m2

               -  Serum total bilirubin ≤ 1.5 mg/dl, except for known Gilbert's disease

               -  Platelet count &gt; 100.000/µl

               -  Hemoglobin &gt; 9g/dl

               -  Neutrophil granulocytes &gt; 1.500/ml

               -  International Normalized Ratio (INR) ≤ 2

          -  Absence of alcohol and/or drug abuse

          -  No other concurrent malignant disease

          -  No inclusion in other clinical trials interfering with the study protocol

          -  No concurrent chronic systemic immune or hormone therapy, except neoadjuvant
             chemotherapy

          -  Absence of any severe organ insufficiency

          -  No pregnancy or breast feeding

          -  Written informed consent

        Exclusion Criteria:

          -  Severe or uncontrolled cardiac insufficiency, including recent (&lt; 6 months) occurrence
             of myocardial infarction, the presence of congestive cardiac insufficiency, of
             symptomatic angor in spite of optimal medical care, of cardiac arrhythmia requiring
             medical treatment presenting insufficient rhythm control, or uncontrolled arterial
             hypertension

          -  Pregnancy or breast feeding

          -  Platinum resistant or refractory disease

          -  Active bacterial, viral or fungal infection

          -  Active gastro-duodenal ulcer

          -  Parenchymal liver disease (any stage cirrhosis)

          -  Uncontrolled diabetes mellitus

          -  Severe obstructive or restrictive respiratory insufficiency

          -  Psychiatric pathology capable of affecting comprehension and judgment faculty

          -  Tumor in the presence of obstruction

          -  Evidence of extra-abdominal disease (with the exception of unilateral malignant
             pleural effusion) or extensive liver metastasis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim P Ceelen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim P Ceelen, MD, PhD</last_name>
    <phone>+32 9 332 62 51</phone>
    <email>wim.ceelen@ugent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charlotte Carlier, MSc</last_name>
    <phone>+ 32 9 332 55 24</phone>
    <email>charlotte.carlier@ugent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Ghent</name>
      <address>
        <city>Ghent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim P Ceelen, MD, PhD, FACS</last_name>
      <phone>09 332 62 51</phone>
      <email>wim.ceelen@ugent.be</email>
    </contact>
    <contact_backup>
      <last_name>Wouter Willaert, MD, PhD</last_name>
      <phone>09 332 8950</phone>
      <email>wouter.willaert@ugent.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013 Apr;10(4):211-24. doi: 10.1038/nrclinonc.2013.5. Epub 2013 Feb 5. Review.</citation>
    <PMID>23381004</PMID>
  </reference>
  <reference>
    <citation>Foley OW, Rauh-Hain JA, del Carmen MG. Recurrent epithelial ovarian cancer: an update on treatment. Oncology (Williston Park). 2013 Apr;27(4):288-94, 298. Review.</citation>
    <PMID>23781692</PMID>
  </reference>
  <reference>
    <citation>Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006 Jan 5;354(1):34-43.</citation>
    <PMID>16394300</PMID>
  </reference>
  <reference>
    <citation>Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001 Feb 15;19(4):1001-7.</citation>
    <PMID>11181662</PMID>
  </reference>
  <reference>
    <citation>Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950-5.</citation>
    <PMID>8960474</PMID>
  </reference>
  <reference>
    <citation>Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005340. Review. Update in: Cochrane Database Syst Rev. 2011;(11):CD005340.</citation>
    <PMID>16437527</PMID>
  </reference>
  <reference>
    <citation>Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst. 2006 Nov 15;98(22):1655-63.</citation>
    <PMID>17105988</PMID>
  </reference>
  <reference>
    <citation>Ceelen WP, Van Nieuwenhove Y, Van Belle S, Denys H, Pattyn P. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012 Jul;19(7):2352-9. doi: 10.1245/s10434-009-0878-6. Epub 2009 Dec 29.</citation>
    <PMID>20039210</PMID>
  </reference>
  <reference>
    <citation>Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008 Nov;44(17):2546-54. doi: 10.1016/j.ejca.2008.07.038. Epub 2008 Sep 11.</citation>
    <PMID>18789678</PMID>
  </reference>
  <reference>
    <citation>Sun X, Li XF, Russell J, Xing L, Urano M, Li GC, Humm JL, Ling CC. Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. Radiother Oncol. 2008 Aug;88(2):269-76. doi: 10.1016/j.radonc.2008.05.015. Epub 2008 Jun 5.</citation>
    <PMID>18538874</PMID>
  </reference>
  <reference>
    <citation>Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007 Dec;18(12):1943-50. Epub 2007 May 11.</citation>
    <PMID>17496308</PMID>
  </reference>
  <reference>
    <citation>Helm CW. The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist. 2009 Jul;14(7):683-94. doi: 10.1634/theoncologist.2008-0275. Epub 2009 Jul 16. Review.</citation>
    <PMID>19608639</PMID>
  </reference>
  <reference>
    <citation>de Bree E, Helm CW. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data. Expert Rev Anticancer Ther. 2012 Jul;12(7):895-911. doi: 10.1586/era.12.72. Review.</citation>
    <PMID>22845405</PMID>
  </reference>
  <reference>
    <citation>Mulier S, Claes JP, Dierieck V, Amiel JO, Pahaut JP, Marcelis L, Bastin F, Vanderbeeken D, Finet C, Cran S, Velu T. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18(25):3793-803. Review.</citation>
    <PMID>22591422</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytoreductive surgery</keyword>
  <keyword>(H)ipec</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Peritoneal carcinomatosis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

